Acute Myelogenous Leukemia  >>  CC-95775  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CC-95775 / BMS
NCT02543879: Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies

Completed
1
94
US
FT-1101, FT1101, Azacitidine
Forma Therapeutics, Inc.
Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma
03/19
03/19

Download Options